Can we all please calm down?
The people who are making the most noise about this broad mechanism of action presented at ASCO are the people who are most heavily invested in it, or those who stand to gain from others becoming more heavily invested.
The presentation by Marnix Bosch at ASCO was NOT a scientific presentation, despite the venue.
It was a highly technical commercial/promotional presentation made during the industry expert theater portion of the meeting, when ASCO essentially sells the stage to whomever wishes to pay the going price for the exposure. The presentation was not peer-reviewed and it was highly biased in favor of the presenter's commercial interest. Therefore, statements about murcidencel's mechanism of action will not have the credibility needed to truly become part of the medical literature, and prescription of murcidencel will not become routine clinical practice in even a single tumor type, much less multiple tumor types, much less other disease states, unless and until the data have been peer-reviewed and vetted by others and perhaps replicated by other scientists.
We make ourselves look bad when we get all excited about a grand slam home run to win the pennant when we haven't even succeeded in getting on base in the first inning of the series.
FIRST THINGS FIRST.
Speaking for myself, I might begin to get a bit more excited after DCVax-L has won approval for a single indication (nd or rGBM) by MHRA, and a little more excited after it has received an indication from the FDA, or EMA, or Health Canada. Those milestones seem a long way off right now, based on current evidence (as opposed to current wishful thinking and speculation).
-- OJ
AI
Market Data 
Markets 
